• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The AFFIRM trial: Rate-control vs. rhythm-control in atrial fibrillation [Classics Series]

byAndrew Cheung, MD MBA
September 22, 2014
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Rate-control, along with anticoagulation, should be the main approach to managing patients with atrial fibrillation.

2. Compared to rhythm-control, rate-control resulted in a lower incidence of adverse events and no significant difference in mortality.

Original Date of Publication: December 5, 2002

Study Rundown: Originally published in 2002, the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial compared two common strategies for managing atrial fibrillation: rhythm-control and rate-control. Patients were anticoagulated in both approaches to address the increased risk of thromboembolic disease in atrial fibrillation. Prior to this study, both rhythm-control and rate-control were considered acceptable strategies, though rhythm-control was often the initial therapy. Rhythm-control involves the use of cardioversion and antiarrhythmic medications to maintain normal sinus rhythm, and this was thought to have benefits, including lowering the risk of stroke and allowing anticoagulation therapy to be discontinued. On the other hand, proponents of the rate-control method argued that rate-control medications were far less toxic than antiarrhythmics, and that there were likely no differences between the two methods in terms of patient-important outcomes.

To address this conflict, the AFFIRM trial was designed to assess the differences in long-term outcomes associated with these two treatment approaches. Patients in the rhythm-control group could be treated with specific antiarrhythmic agents or cardioversion, as decided by their treating physician. Rate-controlled patients were managed using beta-blockers, calcium channel blockers, digoxin, or a combination of these medications. In summary, there was no significant difference between the two groups in mortality (HR 1.15; 95%CI 0.99-1.34). Moreover, there was no significant difference between the two groups in the rates of the secondary endpoint of death, disabling stroke, disabling anoxic encephalopathy, major bleeding, and cardiac arrest (p=0.33). The risk of torsade de pointes, cardiac arrest, and hospitalization, however, were significantly higher in the rhythm-control group.

Click to read study in NEJM

In-Depth [randomized, controlled study]: A total of 4,060 patients were enrolled in the trial and followed for a mean of 3.5 years. They were randomized to the rhythm-control strategy (i.e., treatment with antiarrhythmic medications) or the rate-control strategy (i.e., controlling heart rate with beta-blockers, calcium-channel blockers, digoxin). Patients were included if they were ≥65 years of age, they had atrial fibrillation that was likely to be recurrent, long-term treatment of their atrial fibrillation was warranted, and they were eligible for anticoagulation therapy. The primary endpoint was mortality. The secondary endpoint was a composite of death, disabling stroke, disabling anoxic encephalopathy, major bleeding, and cardiac arrest.

RELATED REPORTS

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

Sleep disorders and insomnia may be strongly associated with atrial fibrillation

Wellness Check: Sleep

There was no significant difference in mortality between the two groups (HR 1.15; 95%CI 0.99-1.34). The rate of the secondary endpoint was also not significantly different between the two groups (p=0.33). There was significantly higher incidence of torsade de pointes, cardiac arrest (i.e., pulseless electrical activity, bradycardia, or other rhythm), and hospitalization after baseline in the rhythm-control group compared to the rate-control group. It was also demonstrated that individuals in the rhythm-control group experienced significantly higher incidence of adverse drug events, including pulmonary events, gastrointestinal events, bradycardia, and prolongation of the QT interval (p<0.001). There was no significant difference between the two groups in the incidence of stroke.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: atrial fibrillation
Previous Post

The RE-LY trial: Dabigatran non-inferior to warfarin in preventing strokes in patients with atrial fibrillation [Classics Series]

Next Post

New clinical prediction model helps emergency physicians identify high-priority febrile children

RelatedReports

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]
Cardiology

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

August 11, 2022
β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Sleep disorders and insomnia may be strongly associated with atrial fibrillation

July 11, 2022
Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

July 7, 2022
#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk
StudyGraphics

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

June 28, 2022
Next Post
New clinical prediction model helps emergency physicians identify high-priority febrile children

New clinical prediction model helps emergency physicians identify high-priority febrile children

Frequent meals linked with lower body weight in children and adolescents

Frequent meals linked with lower body weight in children and adolescents

Children still hospitalized and treated for ITP despite conservative guidelines

Children still hospitalized and treated for ITP despite conservative guidelines

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Same appointment mammogram results may result in less stress for patients being screened for breast cancer
  • Increased use of pediatric CT poses significant oncogenic risk [Classics Series]
  • Pediatric asthma morbidity is associated with geographic location and social determinants of health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.